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Highlights 
•SABR may cause a small decline in lung volumes and DLCO. 
•Baseline pulmonary function was not associated to radiation-induced lung toxicity and survival. 
•Radiation-induced lung toxicity was not clearly associated with dose-volume parameters. 
•Quality of life was globally not impaired, with only a slight decline in one item (fatigue). 
 
Abstract 
Objectives 
To analyze changes in pulmonary function and quality of life (QoL) at different time points after 
Stereotactic Ablative Radiotherapy (SABR) for early stage inoperable lung cancer, and potential correlations 
between radiation dose-volume parameters and pulmonary toxicity or changes in pulmonary function tests 
(PFT) and QoL. 
Materials and methods 
From July 2012 to October 2013, 30 patients were enrolled in this prospective observational study. 
Complete PFT were performed and Lung Cancer Symptoms Scale (LCSS) questionnaire administered prior to 
SABR; all patients then underwent Computed Tomography (CT) scan and PFT at 45, 135, 225 and 315 days 
after SABR, together with LCSS questionnaire. Clinical lung toxicity and radiological toxicity (acute and late) 
were prospectively recorded by using the Radiation Therapy Oncology Group (RTOG) scoring system. 
Results 
A decline in Slow Vital Capacity (SVC), Forced Expiratory Volume in 1 s (FEV1), Single-breath lung diffusing 
capacity (DLCO) and blood partial pressure of oxygen (PaO2) was seen at 135 days post-SABR. PaO2 values 
rescued to normal levels at 315 days. None of the baseline PFT parameters resulted to be associated with 
the occurrence of pulmonary toxicity or with late radiological changes. Mean V5, V10, and V20 and MLD2Gy 
were higher in patients who developed radiation pneumonitis, even if not significantly associated at Cox 
regression analysis. LCSS QoL showed a significant worsening of the single item fatigue at 135 days after 
SABR. 
Conclusions 
A small (mean 10%) but significant decline in lung volumes and DLCO was recorded after SABR, with clinical 
impact of such change difficult to estimate in individual patients. Global QoL was not significantly impaired. 
Dose-volume parameters did not emerge as significantly predictive of any clinical, radiological or functional 
toxicity. 
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1. Introduction 
Stereotactic Ablative Radiotherapy (SABR) is currently recognized as the gold standard for patients with 
inoperable stage I non-small cell lung cancer (NSCLC) [1]. This recommendation is based on the results of 
several prospective phase II trials [2], [3], [4], [5] and [6], as well as large observational studies [7], 
[8] and [9], with variable follow-up intervals: most of them were limited to spirometric parameters and 
diffusing capacity for carbon monoxide (Diffusion Lung capacity for Carbon monoxide, DLCO). Recently, a 
more comprehensive analysis of “complete” Pulmonary Function Tests (including blood gas analysis) was 
reported, on a series of patients enrolled in the RTOG 0236 phase II trial of SABR in inoperable patients 
[10]. 
Primary aim of this prospective study was to investigate changes in pulmonary function after SABR and 
correlation between baseline pulmonary function tests and any pulmonary toxicity and efficacy. Additional 
goals were to analyze possible correlation between radiation-dose volume parameters and lung toxicity 
(clinical or radiological) or impairment in pulmonary function and patient-reported quality of life. 
2. Material and methods 
2.1. Patients 
From July 2012 to October 2013, 30 patients affected with inoperable Stage I NSCLC accepted to be 
enrolled in the study. Eligibility criteria for SABR were: (a) medical contraindications to surgery after 
multidisciplinary evaluation (thoracic surgeon, medical oncologist and pneumologist), (b) ECOG 
Performance Status ≤2, (c) complete staging including 18 fluorodeoxyglucose-Positron Emission 
Tomography (18FDG-PET) and brain Computed Tomography (CT) scan, (d) no prior radiation therapy to the 
site of SABR. Histological diagnosis was not mandatory. In the absence of the cyto-histological evidence of 
malignancy, a new or growing lesion on CT scan was considered consistent with malignancy, in conjunction 
with an increased uptake of 18FDG-PET (according to the concept of “clinical proof of malignancy”). 
2.2. Pulmonary function evaluation 
Fig. 1 illustrates the study flow. Our Institution’s Ethical Review Board approved the study protocol and 
each patient gave informed consent. Lung volumes were measured according to American Thoracic Society 
(ATS)/European Respiratory Society (ERS) Standardization [11], with subjects sitting in a body 
plethysmograph (Vmax Encore 62CareFusion®, Hoechberg Germany) and panting at the end of tidal 
expiration against a closed shutter at a frequency slightly <1 Hz with their cheeks supported by hands. Total 
lung capacity (TLC) was obtained as the sum of thoracic gas volume and the linked inspiratory capacity. 
Functional residual capacity (FRC) was obtained from thoracic gas volume corrected for any difference 
between the volume at which the shutter was closed and the average end-expiratory volume of the four 
preceding regular tidal breaths. Residual volume was the difference between TLC and vital capacity (VC). 
The DLCO was measured using a gas mixture containing 0.3% CO, 0.3% methane, 21.0% O2 and balance N2, 
according to ATS/ERS recommendations [12]. The DLCO was corrected for hemoglobin and 
carboxyhemoglobin obtained by the arterial blood sampling performed on the same day. Predicted values 
for spirometry, lung volumes and DLCO were from Quanjer et al. [13]. Always in a seated position, an 
arterial sample was obtained and blood gas analysis was performed measuring acid-base balance and the 
arterial partial pressure for oxygen (PaO2, mmHg) and carbon dioxide (PaCO2 mmHg) with an ABL 800
® 
series emogasanalyzer (Radiometer, Copenhagen, Denmark). 
 
Fig. 1.  
Study flow. 
2.3. Radiation therapy 
Four-dimensions CT was performed in every patient and an Internal Target Volume (ITV) was defined in 
which the GTV included the tumor position in all phases of the normal respiratory cycle, outlined using a CT 
windows setting. The ITV was expanded by 3 mm to create the planning target volume (PTV). Treatments 
were planned as single arc Volumetric Modulated Arc Therapy, and delivered with an Elekta Axesse™ Linear 
Accelerator (Elekta, Stockholm, Sweden), with 6–10 MV photons and cone-beam CT image-guidance. The 
total dose ranged from 45 to 60 Gy in 3–8 fractions, on the basis of tumor location (45-54 Gy/3 fractions for 
parenchymal lesions; 55 Gy/5 fractions for lesions close to chest wall; 60 Gy/8 fractions for central lesions), 
prescribed at 80% isodose. Mean Lung Dose was kept below 15 Gy2[14]. Dose constraints for esophagus, 
heart, great vessels, trachea, main bronchi and spinal cord were derived from the American Association of 
Physicists in Medicine (AAPM) Task Group 101 recommendation [15]. 
2.4. Study flow 
Clinical examination, total body CT scan and complete PFT were performed at T45, T135, T225 and T315 
(Fig. 1). Lung toxicity was graded according to RTOG acute radiation toxicity score (for events occurring 
within 6 months from the start of radiation treatment) or RTOG late radiation toxicity score (for events 
occurring after 6 months) (http://www.rtog.org/members/toxicity). Acute radiological toxicity was scored 
using a five-point scoring system developed by Vrije University, modified from Kimura et al. [16] (1 = diffuse 
consolidation, 2 = patchy consolidation, 3 = diffuse “ground glass opacity”, 4 = patchy “ground glass 
opacity”, 5 = no changes) [17]. Late radiological toxicity was scored according to the Koenig’s Scale 
(0 = absence of changes, 1 = modified conventional pattern, 2 = mass like pattern, 3 = scar like pattern) 
[18]. 
2.5. Quality of life 
Disease-related symptoms and quality of life were assessed with the patient-reported Lung Cancer 
Symptom Scale (LCSS) questionnaire [19]. This scale focuses on symptoms and their effect on the patient. 
Symptoms assessed were loss of appetite (item 1), fatigue (item 2), cough (item 3), dyspnea (item 4), 
hemoptysis (item 5), pain (item 6), symptom distress (item 7), interference with activity level (item 8), and 
overall quality of life (item 9). Each item is assessed with a 100 mm visual analogue scale, with lower values 
representing better quality of life or lower symptom burden than higher values. Patients were expected to 
complete one LCSS questionnaire at baseline, and then at T135, T225, and T315. 
2.6. Statistics 
All statistical analyses were done on SPSS 20.0 (SPSS Inc., Chicago, USA). Changes in PFT were calculated by 
comparison of the mean values at any time point by Student’s T test. Logistic regression models were used 
to investigate the relationship between PFT and clinical (RTOG any grade, RTOG grade ≥2) and radiological 
status (late toxicity according to Koenig, 0 vs. 1–3). The possible relation between normal lung radiation 
dose and the occurrence of pulmonary toxicity was performed using Fisher's exact test; statistical 
significance was established at p < 0.05. All the categorical variables were evaluated by Pearson’s Chi-
Square Test or Fisher’s Exact test, as appropriate. Survival curves were generated using Kaplan–Meier 
method, starting from the end of radiotherapy, and comparisons were performed using the Mantel–Cox 
log-rank test. The relationship between PFT and overall survival was evaluated using the Cox proportional 
hazards model. 
3. Results 
3.1. Descriptive analysis 
Detailed patients characteristics are presented in Table 1. Mean age was 77 years old (range 61–84); most 
patients were male, with good performance status and stage IA disease. Histologic or cytological diagnosis 
was available in 70% of the cases. The majority of patients were considered medically inoperable for 
concomitant cardiovascular disease and/or poor pulmonary function. 
Table 1.  
Patients’ characteristics. 
Age (mean, range) 77 (61–84) 
Male 23 (76.7%) 
Female 7 (23.3%) 
Former smokers 19 (63.3%) 
Active smokers 8 (26.7%) 
Never smokers 3 (10%) 
Performance status (ECOG) 
0 23 (76.7%) 
1 6 (20%) 
2 1 (3.4%) 
AA Charlson CI (mean, range) 6.9 (3–14) 
<7 16 (53.3%) 
≥7 14 (46.7%) 
Stage 
IA 17 (56.7%) 
IB 13 (43.3%) 
Tumor max diameter, mm (mean, range) 25.5 (12–55) 
Histology 
Adenocarcinoma 9 (30%) 
Squamous cell carcinoma 8 (26.7%) 
NSCLC NOS 4 (13.3%) 
Unknown 9 (30%) 
Age (mean, range) 77 (61–84) 
Treatment schedules 
45–54 Gy/3 fr 9 (30%) 
55 Gy/5 fr 11 (37%) 
60 Gy/8 fr 10 (33%) 
Abbreviations: AA Charlson CI (age-adjusted Charlson comorbidity index); NSCLC (non small cell 
lung cancer); VMAT (volumetric-modulated arc therapy); Gy (gray); fr (fractions). 
*T-stage according to the revised 7th edition of the TNM classification for lung cancer. 
3.2. Baseline and changes in PFT 
PFT distribution at baseline is presented in Table 2. At days 45, 135, 225 and 315, 30 patients (100%), 28 
patients (93.3%), 25 patients (83.3%) and 20 (66.7%) patients were evaluable, respectively. Main reasons of 
drop-off were death (4 patients) and poor compliance (6 patients). 
Table 2.  
Pulmonary function tests distribution. 
Pulmonary 
function test 
Baseline 
(n = 30) 
 
Days 45 post-SABR 
 
Days 135 post-SABR 
 
Days 225 post-SABR 
 
Days 315 post-SABR 
 
 
N Raw n Raw 
Change 
since 
baseline 
n Raw 
Change 
since 
baseline 
n Raw 
Change 
since 
baseline 
n Raw 
Change 
since 
baseline 
FEV1 (liters) 
3
0 
1.7 ± 0.5 
3
0 
1.7 ± 0.5 
−0.01 ± 0.1
8 
2
8 
1.6 ± 0.5 
−0.73 ± 0.2
2 
2
5 
1.6 ± 0.5 
−0.79 ± 0.2
3 
2
0 
1.5 ± 0.5 
−0.19 ± 0.3
3 
FEV1 (% 
predicted) 
3
0 
75.3 ± 23.
1 
3
0 
75.5 ± 24.
4 
−0.49 ± 7.5
3 
2
8 
72.4 ± 25.
1 
−3.21 ± 9.1
8 
2
5 
72.9 ± 2
6.3 
−3.26 ± 9.4
9 
2
0 
64.3 ± 23.
4 
−7.57 ± 11.
66 
FEV1/SVC 
3
0 
61.6 ± 13.
3 
3
0 
60.0 ± 12.
9 
−1.12 ± 3.7
4 
2
8 
59.8 ± 13.
1 
−0.93 ± 4.2
6 
2
5 
59.1 ± 1
4.2 
−0.84 ± 5.6
8 
2
0 
57.1 ± 14.
0 
−1.85 ± 6.8
5 
FEV1/SVC 3 82.2 ± 19. 3 80.3 ± 18. −1.41 ± 5.2 2 79.7 ± 18. −1.19 ± 6.4 2 78.7 ± 1 −0.72 ± 7.3 2 76.1 ± 19. −2.14 ± 9.3
Pulmonary 
function test 
Baseline 
(n = 30) 
 
Days 45 post-SABR 
 
Days 135 post-SABR 
 
Days 225 post-SABR 
 
Days 315 post-SABR 
 
 
N Raw n Raw 
Change 
since 
baseline 
n Raw 
Change 
since 
baseline 
n Raw 
Change 
since 
baseline 
n Raw 
Change 
since 
baseline 
(%predicted) 0 1 0 3 3 8 5 8 5 9.9 3 0 9 5 
SVC (liters) 
3
0 
2.9 ±  0.8 
3
0 
2.9 ± 0.8 0.06 ± 0.24 
2
8 
2.8 ± 0.9 
−0.10 ± 0.3
3 
2
5 
2.8 ± 0.7 
−0.12 ± 0.3
4 
2
0 
2.7 ± 0.7 
−0.26 ± 0.6
6 
SVC (% 
predicted) 
3
0 
92.1 ± 21.
8 
3
0 
94.5 ± 23.
5 
1.05 ± 8.45 
2
8 
91.2 ± 25.
9 
−2.56 ± 14.
67 
2
5 
92.3 ± 2
3.9 
−3.12 ± 10.
62 
2
0 
84.3 ± 20.
8 
−7.33 ± 16.
88 
RV (liters) 
3
0 
3.2 ±  1 
3
0 
3.0 ± 1 
−0.12 ± 0.5
4 
2
8 
3.0 ± 1.0 
−0.97 ± 0.5
4 
2
5 
2.8 ± 0.9 
−0.34 ± 0.5
2 
2
0 
3.0 ± 1.2 
−0.22 ± 0.6
9 
RV (% 
predicted) 
3
0 
130.4 ± 4
7.0 
3
0 
123.6 ± 4
6.8 
−5.02 ± 21.
26 
2
8 
123.9 ± 4
9.3 
−4.4 ± 21.5
3 
2
5 
117.6  
± 45.4 
−14.28 ± 20
.39 
2
0 
123.3 ± 5
8.7 
−8.94 ± 28.
38 
TLC (liters) 
3
0 
6.0 ± 1.4 
3
0 
5.9 ± 1.4 
−0.11 ± 0.5
4 
2
8 
5.7 ± 1.5 
−0.19 ± 0.6
1 
2
5 
5.6 ± 1.3 
−0.46 ± 0.7
3 
2
0 
5.7 ± 1.5 
−0.47 ± 0.9
7 
TLC (% 
predicted) 
3
0 
103.2 ± 2
0.2 
3
0 
100.9 ± 2
0.9 
−2.11 ± 8.7
7 
2
8 
99.3 ± 22.
5 
−3.73 ± 11.
09 
2
5 
96.9 ± 2
1.7 
−8.46 ± 10.
45 
2
0 
96.2 ± 
25.7 
−7.81 ± 14.
25 
DLCO 
(ml/min/mm
Hg) 
3
0 
14.7 ± 4.5 
3
0 
13.3 ± 4.4 
−1.48 ± 2.3
6 
2
8 
13.5 ± 3.9 
−1.50 ± 2.6
3 
2
5 
13.1 ± 3.
3 
−1.73 ± 3.2
2 
2
0 
11.6 ± 4.6 
−3.57 ± 3.5
5 
DLCO (% 
predicted) 
3
0 
67.0 ± 18.
5 
3
0 
60.8 ± 18.
8 
−6.35 ± 11.
34 
2
8 
62.2 ± 16.
4 
−6.32 ± 11.
56 
2
5 
60.6 ± 1
7.2 
−6.84 ± 14.
83 
2
0 
51.6 ± 17.
6 
−14.61 ± 14
.85 
DLCO/VA 
(ml/min/mm
Hg) 
3
0 
3.5 ± 1.4 
3
0 
3.1 ± 0.9 −0.4 ± 1.23 
2
8 
3.2 ± 0.9 
−0.41 ± 1.3
4 
2
5 
3.2 ± 0.8 
−0.39 ± 15.
2 
2
0 
2.9 ± 0.8 
−0.68 ± 1.4
3 
DLCO/VA (% 
predicted) 
3
0 
90.2 ± 27.
3 
3
0 
84.0 ± 26.
3 
−5.9 ± 12.4
5 
2
8 
86.5 ± 29.
5 
−5.32 ± 14.
72 
2
5 
85.0 ± 2
4.3 
−3.92 ± 15.
2 
2
0 
77.6 ± 23.
9 
−10.0 ± 16.
33 
PaO2 3
75.1 ± 8.5 
3
73.1 ± 9.7 −1.7 ± 7.89 
2
72.7 ± 8.8 
−3.11 ± 7.5 2 76.2 ± 6. −1.14 ± 7.6 2 74.6 ± 10. −1.02 ± 8.8
Pulmonary 
function test 
Baseline 
(n = 30) 
 
Days 45 post-SABR 
 
Days 135 post-SABR 
 
Days 225 post-SABR 
 
Days 315 post-SABR 
 
 
N Raw n Raw 
Change 
since 
baseline 
n Raw 
Change 
since 
baseline 
n Raw 
Change 
since 
baseline 
n Raw 
Change 
since 
baseline 
(mmHg) 0 0 8 6 5 4 3 0 3 3 
PaCo2 
(mmHg) 
3
0 
38.3 ± 4.4 
3
0 
37.4 ± 3.7 
−0.95 ± 4.0
5 
2
8 
37.7 ± 4.5 −0.48 ± 3.5 
2
5 
37.8 ± 3.
6 
0.32 ± 3.16 
2
0 
37.8 ± 4.7 
−0.66 ± 5.1
8 
Abbreviations: FEV1 = forced expiratory volume in the first second; SVC = slow vital capacity; 
RV = residual volume; TLC = total lung capacity; DLCO = diffusing capacity for carbon monoxide; 
DLCO/VA diffusing capacity for carbon monoxide / alveolar volume; PaO2 = partial pressure of 
arterial oxygen; PaCO2 = partial pressure of arterial carbon dioxide; SABR = stereotactic ablative 
radiation therapy. 
Table 2 also describes all changes at different time points for any parameter. A statistically significant 
decline in SVC, FEV1, DLCO and PaO2 was seen at 135 days post-SABR; in details, change from baseline was 
0.10 L for SVC (p = 0.04), 0.73 L for FEV1 (p = 0.02), 1.50 ml/min/mmHg for DLCO (p = 0.001) and 3.11 mmHg 
for PaO2 (p = 0.04). At 315 days, a significant change of TLC, FEV1, and DLCO was also evident (p = 0.03, 
0.007 and 0.0001, respectively); conversely, PaO2 values increased at 315 days towards baseline values. For 
DLCO, mean decline at 135 days was 10.6%, while at 315 days 23.2%. The ratio between DLCO and alveolar 
volume didn't show any statistical significant change. No significant correlations were found between 
different tumor location (upper versus lower lobe and central versus peripheral) and changes in PFT. 
3.3. Toxicity 
Clinical pulmonary toxicity according to RTOG scoring system was recorded in 16 patients; 5 patients 
experienced G1 (15%), 6 G2 (20%), 4 G3 (13.3%) and 1 G4 toxicity (3.3%), respectively. At logistic regression 
analysis, none of the baseline PFT parameters resulted to be associated with the occurrence of pulmonary 
toxicity of any grade and of grade ≥2 (Table 3). Other symptoms reported by the patients were asthenia (15 
patients), cough (3 patients) and thoracic pain (1 patient, treated for a tumor in close proximity to the chest 
wall). 
Table 3.  
Logistic regression model analysis of baseline pulmonary function tests and toxicity. 
Pulmonary function 
test 
Any pulmonary toxicity 
 
Grade 2+ pulmonary toxicity 
 
Any late radiological toxicity 
(Koenig) 
 
 
No. of 
events/total 
OR (95% CI) 
p 
Value 
No. of 
events/total 
OR (95% CI) 
p 
Value 
No. of 
events/total 
OR (95% CI) 
p 
Value 
FEV1 (liters) 16/30 
NA-
unstable 
– 11/30 
NA-
unstable 
– 7/24 
16 (0.1–
200) 
0.26 
FEV1 (%predicted) 16/30 
1.5 (0.1–
22) 
0.75 11/30 
3.1 (0.4–
21.4) 
0.26 7/24 
NA-
unstable 
– 
FEV1/SVC 16/30 
NA-
unstable 
– 11/30 
NA-
unstable 
– 7/24 
NA-
unstable 
– 
FEV1/SVC 
(%predicted) 
16/30 
0.02 (0–
7.7) 
0.2 11/30 0.02 (0–7) 0.18 7/24 
NA-
unstable 
– 
SVC 16/30 
NA-
unstable 
– 11/30 
NA-
unstable 
– 7/24 
0.1 (0.003–
7.8) 
0.34 
SVC (%predicted) 16/30 0.1 (0–5) 0.22 11/30 0.1 (0–6.7) 0.21 7/24 
NA-
unstable 
– 
RV (liters) 16/30 
NA-
unstable 
– 11/30 
NA-
unstable 
– 7/24 
NA-
unstable 
– 
RV (%predicted) 16/30 
5.04 (0.4–
75.2) 
0.24 11/30 
8.6 (0.5–
150.3) 
0.14 7/24 
NA-
unstable 
– 
TLC (liters) 16/30 
NA-
unstable 
– 11/30 
NA-
unstable 
– 7/24 
0.7 (0.1–
3.6) 
0.68 
TLC (%predicted) 16/30 
0.03 (0–
5.5) 
0.19 11/30 
0.008 (0–
2.8) 
0.11 7/24 
NA-
unstable 
– 
DLCO 
(ml/min/mmHg) 
16/30 
NA-
unstable 
– 11/30 
0.001 (0–
6.5) 
0.12 7/24 
0.9 (0.6–
1.2) 
0.39 
DLCO (%predicted) 16/30 
8.8 (0.6–
136) 
0.12 11/30 
8.8 (0.7–
105.4) 
0.09 7/24 
NA-
unstable 
– 
Pulmonary function 
test 
Any pulmonary toxicity 
 
Grade 2+ pulmonary toxicity 
 
Any late radiological toxicity 
(Koenig) 
 
 
No. of 
events/total 
OR (95% CI) 
p 
Value 
No. of 
events/total 
OR (95% CI) 
p 
Value 
No. of 
events/total 
OR (95% CI) 
p 
Value 
DLCO/VA 
(ml/min/mmHg) 
16/30 
NA-
unstable 
– 11/30 
NA-
unstable 
– 7/24 
NA-
unstable 
– 
DLCO/VA 
(%predicted) 
16/30 
3.9 (0.3–
55) 
0.31 11/30 
3.7 (0.2–
75.2) 
0.4 7/24 
NA-
unstable 
– 
PaO2 (mmHg) 16/30 
1.0 (0.8–
1.3) 
0.94 11/30 
0.9 (0.5–
1.6) 
0.72 7/24 
1.1 (0.9–
1.3) 
0.41 
PaCo2 (mmHg) 16/30 
0.8 (0.1–
4.3) 
0.75 11/30 
0.3 (0.1–
1.3) 
0.12 7/24 
NA-
unstable 
– 
Abbreviations: CI = confidence interval; OR = odds ratio; NA = not applicable; all others abbreviation 
are as shown in Table 2. 
Concerning acute radiological toxicity, data are available for 30 and 27 patients at 45 days and 135 days, 
respectively; 22/30 patients (73%) had some nonspecific radiological changes at these time points; 8/22 
patients (36.4%) had CT findings of consolidation pattern (patchy in 3 and diffuse in 5), while 14 (63.4%) 
presented ground-glass opacities (patchy in 5 and diffuse in 9). At 225 days and 315 days after SABR, data 
of 24 and 16 patients were available, respectively. Eight patients out of 24 (33.3%) did not develop any kind 
of late radiological changes, while 9/24 (37.5%) developed a mass-like consolidation pattern. 
At logistic regression, performed on 24 evaluable patients, baseline PFT did not result associated to late 
radiological changes. 
3.4. Correlation between dose-volume parameters, lung toxicity and changes in PFT 
Patients who developed radiation pneumonitis (any grade) had higher volume of normal lung receiving 5, 
10 and 20 Gy (V5Gy, V10Gy, V20Gy) and higher Mean Lung Dose (MLD2Gy, converted for fractionation in 2 Gy 
equivalent). We also considered as a potential predictive parameter of lung toxicity the absolute lung 
volume spared from a 5 Gy dose (VS5). Logistic regression analysis did not show any significant correlation 
between these dosimetric parameters and a higher risk of clinical toxicity (Table 4). The same was observed 
for radiological toxicity and for PFT changes (data not shown). 
Table 4.  
Normal lungs dose-volume distributions by development of any grade clinical lung toxicity. 
Parameter All patients Pneumonitis No pneumonitis 
  
 
(n = 30) (n = 14) (n = 16) OR (95% CI) P value 
Ipsilateral lung V20Gy (%) 15.6 ± 5.5 15.1 ± 5.8 16.1 ± 5.4 1.03 (0.91–1.18) 0.61 
Ipisilateral lung V10Gy (%) 24.5 ± 6.8 22.9 ± 6.9 26.1 ± 6.5 1.07 (0.96–1.21) 0.22 
Ipsilateral lung V5Gy (%) 34.9 ± 8.6 31.7 ± 8.2 38.1 ± 8.0 1.11 (0.99–1.24) 0.058 
Ipsilateral mean lung dose (EQD2Gy) 11.9 ± 3.5 11.7 ± 3.9 12.1 ± 3.1 1.03 (0.83–1.27) 0.82 
Bilateral lung V20Gy (%) 7.8 ± 2.6 7.8 ± 2.8 7.8 ± 2.6 0.99 (0.75–1.32) 0.97 
Bilateral lung V10Gy (%) 14.4 ± 5.1 14.6 ± 6.1 14.2 ± 3.9 0.98 (0.85–1.14) 0.84 
Bilateral lung V5Gy (%) 24.8 ± 7.4 24.7 ± 8.9 24.8 ± 6.0 1.0 (0.90–1.10) 0.97 
Bilateral mean lung dose (EQD2Gy) 6.9 ± 1.9 7.0 ± 2.2 6.9 ± 1.6 0.98 (0.66–1.44) 0.91 
Absolute lung volume spared from a 5 Gy dose (VS5, in cc) 3088.9 ± 790.3 3157.4 ± 699 3020.4 ± 893.5 1.02 (0.78–1.17) 0.65 
Abbreviations: CI = confidence interval; OR = odds ratio; V = volume receiving n Gy (e.g., 
V20 = volume receiving 20 Gy); EQD2Gy = equivalent dose in 2 Gy fractions. 
3.5. Survival 
At the time of data analysis, 4 patients (13.3%) were dead. Two deaths were due to disease progression (1 
at 12 and 1 at 14 months from SABR); one patient died for acute heart failure (at 2 months from SABR) and 
one for rapid disease progression in chronic lymphatic leukemia (at 3 months from SABR). Kaplan-Meier 
survival analysis was performed in order to investigate whether baseline PFT parameters had a potential 
influence. Fig. 2 shows the overall survival curves for patients with PFT parameters above and below their 
mean values. None of the baseline PFT parameters resulted significantly associated with overall survival. A 
trend for a negative influence on Overall Survival (OS) was evident for the percentage of predicted DLCO: 
OS at 1 year in patients with DLCO% greater than or equal to the mean value (67% of the predicted value) or 
in patients with DLCO less than the mean value were 100% and 78%, respectively (p =  0.055). Additionally, 
we analyzed the potential influence on survival of the age-adjusted Charlson’s comorbidity index (aa-CCI); 
at univariable analysis, patients with aa-CCI below the mean value (6.9) had better OS rates than patients 
with an aa-CCI above the mean value (0% vs 28.6%, p = 0.009). These results were confirmed at log-rank 
test (p = 0.035, Fig. 2F). 
 
Fig. 2.  
Kaplan-Meier overall survival curves of patients with baseline pulmonary function test values 
greater and less than the mean percentage of predicted values. (2A) Total lung capacity (TLC); (2B) 
residual volume (RV); (2C) forced expiratory volume in the first second FEV1; (2D) slow vital 
capacity (SVC); (2E) diffusing capacity for carbon monoxide (DLCO); (2F) age-adjust Charlson’s 
comorbidity index (aa-CCI). 
3.6. Quality of life 
Compliance for patients completing the LCSS was 80.5% (107 of 133 total assessments); the most common 
reason for non-compliance was failure in questionnaire administration. The analysis was performed at 135 
days, when 22 questionnaires were evaluable. Fig. e3 (Supplementary material) describes the evolution of 
mean values for every item from basal to 135 days after completion of SABR, showing a statistical 
significant worsening of the item 2 “Fatigue” (mean basal value = 29, mean value at T135 = 39.8, p = 0.05). 
Non-significant changes were observed for other items; a negative trend in terms of worsening of cough 
(p = 0.053) and daily activity (p = 0.06) was registered (Fig. 3, Supplementary material). A similar pattern of 
LCSS changes was observed at 315 days after SABR (on 10 evaluable patients, data not shown). At logistic 
regression analysis, no significant correlation was observed between PFT changes and worsening of fatigue. 
4. Discussion 
In a recent review on the role of SABR for early stage lung cancer, from Louie et al. [20], and accompanying 
editorial from Brada et al. [21], the Authors emphasize the need for prospective studies with survival and 
quality of life as primary endpoints, focusing the attention on pulmonary function and morbidity. This is 
one of the few prospective studies describing changes in pulmonary function and quality of life after SABR, 
designed with different endpoints: we investigated for a correlation between SABR and changes in 
pulmonary function, for a potential correlation between baseline pulmonary function tests and overall 
survival, and between radiation-dose volume parameters and lung toxicity or impairment in pulmonary 
function and patient-reported quality of life. This prospective series of patients is heterogeneous with 
regards to the size of lesions, position (central and peripheral) and dose prescription, reflecting clinical 
practice in an academic environment. 
Changes of SVC, FEV1 and DLCO at 135 and TLC, FEV1, and DLCO at 315 days after SABR resulted to be 
statistically significant. The ratio between DLCO and alveolar volume (VA) did not significantly change, 
suggesting that alveolar volume reduction dose impact on DLCO more than true diffusion impairment. 
Conversely, a decline of PaO2 was evident at 135 days, but not at 315 days, suggesting a progressive 
recovery of oxygen level during follow-up. Results of the present study are partially in contrast with the 
findings of Stanic et al. on pulmonary function changes after stereotactic radiotherapy in patients included 
in the RTOG 0236 phase II trial, designed for medically inoperable early stage NSCLC patients [10]. In their 
report, including the data of 55 patients followed over a 2 years interval, the mean percentage in FEV1 and 
DLCO decline were 5.8% and 6.3%, respectively, with minimal changes in blood gases and no significant 
decline in oxygen saturation. The Authors concluded that no clinically significant changes in pulmonary 
function were evident after SABR, at a dose of 54 Gy in 3 fractions. The same statistical methods were used 
to analyze PFT changes over time, and the two studies may be carefully compared, taking into account that 
the RTOG study was designed for a selected group of patients with specific characteristics (peripheral 
tumors, all receiving 54 Gy in 3 fractions). Baseline function tests were better for our patients (mean DLCO: 
14.7 vs. 10.6, mean FEV1: 1.72 vs. 1.3): we can argue that starting from higher baseline values, the entity of 
the reduction might be higher as well, as underlined in the report by Guckenberger et al. [22]. Moreover, 
33% of our patients (n = 8) were treated for centrally located tumors. A difference in treatment planning is 
also evident, as our series include only VMAT plans, while in the RTOG cohort patients were treated with 
3D conformal radiotherapy. 
Another important endpoint in our trial was to investigate whether baseline PFT correlates or not with lung 
toxicity and overall survival. Both studies showed no correlation between baseline PFT and the occurrence 
of any grade clinical or radiological pulmonary toxicity. Moreover, baseline PFT were not associated to 
overall survival probability at 1 year. In a previous study by Henderson et al. [23], baseline FEV1 significantly 
predicted for post-treatment survival, and patients with poor pulmonary function had significantly better 
survival. Another study, from Stephans et al. [24], showed similar results. As underlined by Stanic et al. [10], 
these findings might be explained by the higher rate of deaths in patients medically inoperable for reasons 
other than poor pulmonary function. In our cohort, patients with higher age-adjusted Charlson’s 
comorbidity index (aa-CCI) showed significantly worse survival than the other patients at univariate 
analysis, confirmed at Mantel–Cox log-rank test (p = 0.035). Particularly, cardiac diseases are associated 
with a higher risk of death after SABR, and therefore patients with NSCLC and severe cardiac disease appear 
to have less chance of survival than inoperable patients with poor pulmonary function. 
No relationships between MLD2 Gy, V5Gy, V10Gy, V20Gy (ipsilateral and bilateral), VS5 (bilateral) and the 
occurrence of radiation-induced lung toxicity were observed. A parallel result was obtained when 
investigating for the correlation between the same lung dose-volume parameters and changes in PFT. 
Again, these results are similar to what previously shown in the RTOG 0236 cohort, even if the planning 
technique was different [10]. Notably, the occurrence of lung toxicity in the present study is higher than 
previously reported (grade ≥3 lung toxicity 16.6%): this finding may be a consequence of several factors, 
such as the accurate follow-up protocol typical of a prospective study in comparison with retrospective 
series (toxicity overestimation) or the randomly high number of stage IB (tumors larger than 3 cm) patients 
enrolled in our cohort (44% vs. 20% in the RTOG 0236 cohort). SABR for larger tumors may translate in 
higher doses to normal lungs in comparison with the more typical dose distributions achievable in patients 
with stage IA NSCLC, and the reported toxicity rate for larger tumors is higher [25]. However, as previously 
mentioned, in the present study we did not find any correlation between normal lung dose-volume 
parameters and the occurrence of lung toxicity (clinical and radiological). With regards to the possible 
negative impact of the use of VMAT, a previous publication showed no difference in the incidence of 
radiation pneumonitis between 3D-CRT and VMAT [17]. 
SABR was very well tolerated, with a limited impact on daily life. Previous studies also indicated, by means 
of other scoring systems, that quality of life was not severely impaired by SABR [26], [27] and [28]. 
In conclusion, results of the present study show that SABR may cause a small decline in lung volumes and 
DLCO; however, the clinical impact of such changes seems limited in the whole population, being difficult to 
estimate in individual patients. The lung function worsening observed after SABR appears however of lower 
entity if compared with the expected damage caused by thoracic surgery, even after surgical interventions 
such as wedge resection or segmentectomy. 
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